Modification of Cognitive Performance in Schizophrenia by Complexin 2 Gene Polymorphisms
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
CONTEXT: Schizophrenia is the collective term for a heterogeneous group of mental disorders with a still obscure biological basis. In particular, the specific contribution of risk or candidate gene variants to the complex schizophrenic phenotype is largely unknown. OBJECTIVE: To prepare the ground for a novel "phenomics" approach, a unique schizophrenia patient database was established by GRAS (Göttingen Research Association for Schizophrenia), designed to allow association of genetic information with quantifiable phenotypes.Because synaptic dysfunction plays a key role in schizophrenia, the complexin 2 gene (CPLX2) was examined in the first phenotype-based genetic association study (PGAS) of GRAS [corrected] DESIGN: Subsequent to a classic case-control approach, we analyzed the contribution of CPLX2 polymorphisms to discrete cognitive domains within the schizophrenic population. To gain mechanistic insight into how certain CPLX2 variants influence gene expression and function, peripheral blood mononuclear cells of patients, Cplx -null mutant mice, and transfected cells were investigated. SETTING: Coordinating research center (Max Planck Institute of Experimental Medicine) and 23 collaborating psychiatric centers all over Germany. PARTICIPANTS: One thousand seventy-one patients with schizophrenia (DSM-IV) examined by an invariant investigator team, resulting in the GRAS database with more than 3000 phenotypic data points per patient, and 1079 healthy control subjects of comparable ethnicity. Main Outcome Measure Cognitive performance including executive functioning, reasoning, and verbal learning/memory. RESULTS: Six single-nucleotide polymorphisms, distributed over the whole CPLX2 gene, were found to be highly associated with current cognition of schizophrenic subjects but only marginally with premorbid intelligence. Correspondingly, in Cplx2 -null mutant mice, prominent cognitive loss of function was obtained only in combination with a minor brain lesion applied during puberty, modeling a clinically relevant environmental risk ("second hit") for schizophrenia. In the human CPLX2 gene, 1 of the identified 6 cognition-relevant single-nucleotide polymorphisms, rs3822674 in the 3' untranslated region, was detected to influence microRNA-498 binding and gene expression. The same marker was associated with differential expression of CPLX2 in peripheral blood mononuclear cells. CONCLUSIONS: The PGAS allows identification of marker-associated clinical/biological traits. Current cognitive performance in schizophrenic patients is modified by CPLX2 variants modulating posttranscriptional gene expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Membrane Fusion: Grappling with SNARE and SM Proteins
Südhof, T. C., & Rothman, J. E. (2009) · Science · doi:10.1126/science.1161748 · Cited by 2,027
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Common variants conferring risk of schizophrenia
†Genetic Risk and Outcome in Psychosis (GROUP), Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., Werge, T., Pietiläinen, O. P. H., Mors, O., et al. (2009) · Nature · doi:10.1038/nature08186 · Cited by 1,677
Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods.
Aickin, M., & Gensler, H. (1996) · American Journal of Public Health · doi:10.2105/ajph.86.5.726 · Cited by 1,346
Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
Stephan, K. E., Friston, K. J., & Frith, C. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn176 · Cited by 1,134 · cited 1×
“Numerous reports have implicated genes encoding synaptic proteins in the etiology of schizophrenia.(10,11) Postmortem studies on the brain tissue of schizophrenic patients have consistently observed alterations in the expression of several synaptic proteins.”
BackgroundA key role for corticotropin-releasing factor in alcohol dependence
Heilig, M., & Koob, G. F. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.06.006 · Cited by 503
Alterations of the microRNA network cause neurodegenerative disease
Hébert, S. S., & De Strooper, B. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.12.003 · Cited by 452 · cited 2×
“These results suggest a role of SNP rs3822674 in posttranscriptional regulation of CPLX2 expression that may become relevant on miR profile changes in specific neuronal subsets in response to, for example, brain injury.(38)”
BackgroundEastwood, S. L., & Harrison, P. J. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000741 · Cited by 170
Xue, M., Stradomska, A., Chen, H., Brose, N., Zhang, W., Rosenmund, C., & Reim, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803012105 · Cited by 137
Self-citation
Cited by
MicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
Organ aging signatures in the plasma proteome track health and disease
Oh, H. S.-H., Rutledge, J., Nachun, D., Pálovics, R., Abiose, O., Moran-Losada, P., Channappa, D., Urey, D. Y., Kim, K., Sung, Y. J., et al. (2023) · Nature · doi:10.1038/s41586-023-06802-1 · Cited by 634
Seroprevalence of autoantibodies against brain antigens in health and disease
Dahm, L., Ott, C., Steiner, J., Stepniak, B., Teegen, B., Saschenbrecker, S., Hammer, C., Borowski, K., Begemann, M., Lemke, S., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24189 · Cited by 350
Self-citationHammer, C., Stepniak, B., Schneider, A., Papiol, S., Tantra, M., Begemann, M., Sirén, A.-L., Pardo, L. A., Sperling, S., Mohd Jofrry, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.110 · Cited by 342
Self-citationConvergence of placenta biology and genetic risk for schizophrenia
Ursini, G., Punzi, G., Chen, Q., Marenco, S., Robinson, J. F., Porcelli, A., Hamilton, E. G., Mitjans, M., Maddalena, G., Begemann, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0021-y · Cited by 272
Self-citation
Metadata
- Authors
- Begemann, M., Grube, S., Papiol, S., Malzahn, D., Krampe, H., Ribbe, K., Friedrichs, H., Radyushkin, K. A., El-Kordi, A., Benseler, F., Hannke, K., Sperling, S., Schwerdtfeger, D., Thanhäuser, I., Gerchen, M. F., Ghorbani, M., Gutwinski, S., Hilmes, C., Leppert, R., Ronnenberg, A., Sowislo, J., Stawicki, S., Stödtke, M., Szuszies, C., Reim, K., Riggert, J., Eckstein, F., Falkai, P., Bickeböller, H., Nave, K.-A., Brose, N., & Ehrenreich, H.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2010-09-01
- Volume
- 67
- Issue
- 9
- Pages
- 879
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2155813359
- Cited by
- 94
- References
- 10
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modification of Cognitive Performance in Schizophrenia by Complexin 2 Gene Polymorphisms. https://app.cochat.ai/papers/10.1001/archgenpsychiatry.2010.107
- The paper
- Begemann, M., Grube, S., Papiol, S., Malzahn, D., Krampe, H., Ribbe, K., Friedrichs, H., Radyushkin, K. A., El-Kordi, A., Benseler, F., Hannke, K., Sperling, S., Schwerdtfeger, D., Thanhäuser, I., Gerchen, M. F., Ghorbani, M., Gutwinski, S., Hilmes, C., Leppert, R., . . . Ehrenreich, H. (2010). Modification of Cognitive Performance in Schizophrenia by Complexin 2 Gene Polymorphisms. Archives of General Psychiatry. https://doi.org/10.1001/archgenpsychiatry.2010.107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.